Variant-adapted COVID-19 vaccine boosters enhance humoral immunity and limit IgG4 accumulation in solid cancer patients
Repeated booster doses elicit strong and durable neutralizing antibody responses in solid cancer patients. It seems that variant-adapted formulations may mitigate IgG4 accumulation, thus ideally moderating tolerance associated with IgG4 by introducing antigenic novelty. These findings support continued booster administration and monitoring of humoral responses in oncologic populations.
Authors
- Silvia Stefánia Longoni
- Matteo Valerio (ORCID: https://orcid.org/0000-0001-9156-4941)
- Matteo Verzè
- Sara Caldrer (ORCID: https://orcid.org/0000-0002-2379-1082)
- Sonia Zamboni
- Stefania Gori (ORCID: https://orcid.org/0000-0001-6320-405X)
- Natalia Tiberti (ORCID: https://orcid.org/0000-0002-2981-5233)
- Chiara Piubelli (ORCID: https://orcid.org/0000-0002-5739-3795)
- Federico Giovanni Gobbi (ORCID: https://orcid.org/0000-0002-6899-4545)
- Fabrizio Nicolis (ORCID: https://orcid.org/0009-0002-3186-1965)
- Donato Zipeto (ORCID: https://orcid.org/0000-0002-2168-4144)
- Elisa Orlandi (ORCID: https://orcid.org/0000-0002-1484-4170)
- Natasha Gianesini (ORCID: https://orcid.org/0009-0008-4330-1758)
- Francesco Rizzolo
- Katrine Barbero
- Elisabetta Vezzelli
Institutions
- University of Verona (IT)
- Ospedale Sacro Cuore Don Calabria (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-03
- DOI
- https://doi.org/10.3389/fimmu.2025.1699177
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Ministero della Salute
- Università degli Studi di Verona